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ABSTRACT 
 
Background: Uterine cervical carcinoma is the most gynecological malignancy in women 
worldwide. The most common type of cervical carcinoma histology is squamous cell carcinoma and 
has a better prognosis than adenocarcinoma. Neoadjuvant chemotherapy is the management of 
early-stage cervical carcinoma before radical hysterectomy is performed. In addition to clinical-
pathological factors, biomolecular markers are now being developed and used as parameters for 
evaluating chemotherapy responses. Vascular Endothelial Growth Factor-C is a VEGF derivative 
that plays a role in the process of vasculogenesis, limphangiogenesis, and the formation of new 
lymphatic channels which play an important role in metastasis. This study aimed to examine the 
effect of Paxus-Carboplatin chemotherapy in decreasing VEGF-C in squamous cell cervical 
carcinoma tissue. 
Subjects and Method: This was a quasi experiment study conducted at Department of 
Obstetrics and Gynecology and Pathology Anatomy Laboratory of Dr. Moewardi Hospital/ Faculty 
of Medicine, Universitas Sebelas Maret. 25 tissue samples of squamous cell stage IB2-IIA2 cervical 
carcinoma immunohistochemistry VEGF-C expression was carried out before and after Paxus-
Carboplatin chemotherapy was given. The data were analyzed by Wilcoxon test. 
Results: VEGF-C expression in squamous cell cervical carcinoma tissue after chemotherapy was 
lower (mean = 4.20) than before chemotherapy (mean = 6.16) and it was statistically significant 
(p<0.001). 
Conclusion: Neoadjuvant chemotherapy decreases VEGF-C in squamous cell cervical carcinoma 
tissue. 
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BACKGROUND 
Uterine cervical carcinoma is the fourth 
largest cancer and gynecological cancer in 
women worldwide with a mortality morta-
lity to incidence of 55% (International 
Agency for Research on Cancer, 2012). In 
Indonesia, cervical carcinoma is the most 
common malignancy in women (17.8% ) 
with 40,000 cases of cervical carcinoma 
occurring annually. According to the Indo-
nesian Ministry of Health, currently the 
number of women with new cervical carci-
noma ranges from 90-100 cases per 
100,000 population (Ministry of Health, 
2013). The most common histological types 
of cervical carcinoma were squamous cell 
carcinoma (75.9%) followed by adenocarci-
noma (11.4%), adenosquamose, neuroendo-
crine, and other types (12.7%) (Lindstr, 
2010). Patients with squamous cell cervical 
carcinoma have a better prognosis than 
adenocarcinoma (Wada et al., 2014). Mana-
gement of early-stage cervical carcinoma is 
by giving neoadjuvant chemotherapy before 
radical hysterectomy surgery, especially in 
patients with lesions more than 4 cm or 
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called bulky lesion (RI Ministry of Health, 
2013). Assessment of the chemotherapy 
response has been carried out by seeing a 
large decrease in cervical lesions. However, 
currently biomolecular markers are also 
being developed and used as parameters for 
evaluating chemotherapy responses 
because they are expected to increase the 
success of therapy in patients with cervical 
carcinoma in early stage uterias (Nakamura 
et al., 2014). 
Recent studies have shown the 
importance of tumor angiogenesis as a key 
factor affecting patient survival and the 
prognosis of several gynecological malig-
nant tumors (Mandic, Knezevic, and 
Ivkovic, 2014). Increased levels of Vascular 
Endothelial Growth Factor (VEGF) will 
stimulate angio-genesis activity which is 
part of the metastatic process (Agustiyan-
sah, 2014). Vascular Endothelial Growth 
Factor-C (VEGF-C) is one of the VEGF deri-
vatives that plays a role in vasculogenesis 
and limphangiogenesis. Lymph node meta-
stasis is the main metastatic pathway of 
cancer cells, so lymphangiogenesis is an 
important factor in the metastatic process 
(Chang et al., 2012; Nakamura et al., 2014). 
(Franc et al., 2015) examined the expres-
sion of VEGF-C in cervical carcinoma tissue 
which results in increased VEGF-C expres-
sion in advanced stage cervical carcinoma. 
This shows the importance of VEGF-C as a 
proangiogenic factor in the process of 
cervical carcinoma neoangiogenesis.  
VEGF-C expression is triggered by cell 
hypoxic conditions in large (bulky) cervical 
carcinoma lesions, leading to the emer-
gence of HIF-1α then increasing regulation 
of VEGF gene expression levels and also 
increasing transcriptional activity in the 
VEGF signal transduction pathway (Zhang 
et al. , 2016). 
Study by Zhang et al. (2016) showed 
that VEGF protein expression was signifi-
cantly higher in squamous cell carcinoma 
tissue than normal cervical tissue. In 
addition, high mRNA expression from HIF-
1𝛼 and VEGF was associated with increased 
metastatic potential in carcinoma squa-
mous cell cervix. 
This study studied the expression of 
VEGF-C in the tissue of squamous cell 
cervical carcinoma patients after being 
given neoadjuvant chemotherapy. Exami-
nation of biomolecular markers as a para-
meter for evaluating chemotherapy res-
ponses is expected to bring improvements 
in the management of cervical carcinoma 
patients. Assessment of chemotherapy 
responses using biomarkers is expected to 
be better because it is upstream, more 
objective and has wider benefits. 
 
SUBJECTS AND METHOD 
1. Study Design 
This was a quasi experiment study. The 
study was conducted at Department of Obs-
tetrics and Gynecology and Anatomy 
Pathology Laboratory, Dr Moewardi Hos-
pital/Faculty of Medicine, Universitas 
Sebelas Maret, from September 2017 to 
March 2018. 
2. Study Sample 
A total of 25 samples from tissue biopsy of 
squamous cell stage 2N2A cervical carci-
noma patients performed immunohisto-
chemical VEGF-C expression before and 
after Paxus-Carboplatin chemotherapy was 
given.  
3. Study Variables 
The dependent variable was VEGF-C tissue 
expression. The independent variable was 
neoadjuvant chemotherapy. 
4. Data Analysis 
The data analysis was done using the 
Wilcoxon Test. 
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RESULTS 
The majority of the study subjects were 40-
60 years old (72.0%), elementary school 
education (52.0%), null parity (64.0%), 
stage IIA2 cervical cancer sufferers (88.0%) 
(Table 1).  
The mean results of cervical tissue 
VEGF-C expression after administration of 
neoadjuvant chemotherapy were lower 
(mean= 4.20) than before (mean= 6.16) 
with p<0.001. It showed that there was a 
very significant difference in cervical tissue 
VEGF-C expression before and after the 
administration of neoadjuvant chemo-
therapy. 
Table 1. Sample Characteristics  
Characteristics Category Frequency Percentage 
Age  
< 40 years old 4 16.0% 
40-60 years old 18 72.0% 
> 60 years old 3 12.0% 
Education  
Not Graduated - - 
Elementary school 13 52.0% 
Junior high school 3 12.0% 
Senior high school 7 28.0% 
Diploma - - 
Bachelor  2 8.0% 
Parity 
0 – 2 16 64.0% 
>2 to 4 8 32.0% 
> 4 1 4.0% 
Stadium 
I B2 3 12.0% 
II A2 22 88.0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.Microfotographic description of VEGF-C tissue expression 
A. Before neoadjuvant chemotherapy. B. After neoadjuvant chemotherapy.  
 
Description: Red arrows show VEGF-C expression in the cytoplasm, and yellow arrows show 
intercellular VEGF-C expression. 
B A 
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Table 2. The mean of cervical tissue VEGF-C expression before and after 
neoadjuvant chemotherapy 
Time N 
The mean expression 
of VEGF-C tissue 
p 
Before  25 6.16 < 0.001 
After 25 4.20  
 
 
Figure 2.The mean expression of VEGF-C in the tissue 
 
DISCUSSION 
In this study most of the research subjects 
was 40-60 years old (72%). This was in 
accordance with epidemiological research 
data which stated that the highest age 
group of cervical cancer patients was 45-54 
years old (Aziz, 2009). Regarding the pre-
valence of HPV infection which increased 
with increasing age (Powell et al., 2011). 
The educational background of the 
study subjects was mostly elementary 
school (52.0%) and the parity was mostly 
between 0-2 (64.0%). A low educational 
background was a risk factor for cervical 
carcinoma. Besides sexual activity at a 
young age, having sex with multipartners, 
smoking, low socio-economic conditions, 
the use of birth control pills, sexually trans-
mitted diseases, and impaired immunity 
were the risk factors for cervical carcinoma. 
Stage IIA2 sufferers were more numerous 
than stadium IB2 (88%). This was consist-
ent with the data that most cases (62-82%) 
came at an advanced stage in developing 
countries, such as Indonesia (Aziz, 2009). 
Neoadjuvant chemotherapy was given 
with the aim of reducing the size of lesions 
in the cervix, so that it can reduce angio-
genesis in tumor cells, then can reduce the 
expression of HIF-1α, followed by a 
decrease in transcription of the VEGF-C 
gene (Osman, 2014). As a result, the syn-
thesis of VEGF-C m-RNA has also 
decreased, so it was expected that the 
production of VEGF-C proteins expressed 
in tissues also decreased (Mandic, Kne-
zevic, and Ivkovic 2014; Morfoisse et al., 
2014). In addition, neoadjuvan chemo-
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therapy can also affect the process of 
lymphangiogenesis and angiogenesis and 
kill cancer cells, both locally and meta-
stasized, therefore, the expression of VEGF-
C in cervical tissue was expected to 
decrease after the chemotherapy was given 
(Wang, Li, and Zhao, 2016). 
Multivariate analysis revealed that 
VEGF-C expression was an independent 
factor affecting lymph node metastasis 
(Nakaamura et al., 2014). Metastasis in 
lymph nodes was one of the prognosis 
factors or a free predictor of survival rates. 
Patients without metastasis in lymph nodes 
have a 5-year survival rate of 91%, while 
patients with lymph node metastases have 
an average of 67%. In patients with squa-
mous cell carcinoma of the stage IB-IIIB 
VEGF-C expression was higher than normal 
cervical tissue, and the increase in expres-
sion was directly proportional to the higher 
clinical stage (Franc et al., 2015). 
In this study, there were several limi-
tations. The researchers did not examine 
external factors that could affect the expres-
sion of VEGF-C in cervical tissue squamous 
cell carcinoma. In addition, the chemo-
therapy given in the study was 3 series, 
further study is needed especially for 
advanced cervical carcinoma of the uterus 
given chemotherapy to 6 series. This study 
used an immunohistochemical score that 
was semi quantitative to assess the res-
ponse to chemotherapy. Other quantitative 
tests such as PCR examination will give 
more accurate results. 
Based on the results of the study, it 
can be concluded that the expression of 
VEGF-C in squamous cell cervical carci-
noma tissue decreased significantly in pati-
ents given neoadjuvant chemotherapy, so 
that VEGF-C tissue expression can be used 
as a parameter for evaluating chemo-
therapy responses. 
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